TPG Capital and The Carlyle Group have completed their exit from Australian hospital operator Healthscope, having privatized the company in 2010 and re-listed it last year.
Exits | 24 Nov 2015 |
Indian life-science technology company Take Solutions has agreed to pay INR1.15 billion ($17.4 million) for Ecron Acunova (EA), providing an exit for healthcare-focused private equity firm OrbiMed Advisors.
South Asia | 19 Nov 2015 |
KKR has committed $35 million to Signostics, an Australian medical technology company that produces hand-held devices used to conduct ultrasound tests and bladder scans.
Healthcare | 17 Nov 2015 |
Shanghai-based healthcare-focused PE firm Lyfe Capital has closed its debut China fund at $298 million.
Greater China | 16 Nov 2015 |
Sequoia Capital has partnered with global medical equipment manufacturer Medtronic to form a China-focused medical technology investment fund worth $60 million.
Greater China | 13 Nov 2015 |
The proposed privatization of WuXi PharmaTech, a China-based provider of contract R&D services to the global pharmaceutical sector, has won the support of two major shareholder proxy advisory firms.
Buyouts | 13 Nov 2015 |
Wenzhou Kangning Hospital, a private psychiatric specialty care service provider in China with several PE investors, has priced its Hong Kong IPO to raise as much as HK$681 million ($88 million).
Greater China | 10 Nov 2015 |
The board of Singapore-listed medical devices manufacturer Biosensors International has accepted a buyout offer from CITIC Private Equity that values the company at approximately S$1.4 billion ($996 million).
Greater China | 06 Nov 2015 |
The liberalization of China’s services sector represents a significant opportunity for private equity, although investors must think carefully about targeting appropriate areas and finding the right partners.
Consumer | 05 Nov 2015 |
Lily Asia Venture has provided a Series A round of funding worth $15 million for MabSpace Bioscience, a China-based company focused on developing cancer therapies.
Greater China | 30 Oct 2015 |
CITIC Private Equity has submitted a buyout offer for Biosensors International, a Singapore-listed medical devices manufacturer in which it already holds close to a 20% stake.
Buyouts | 29 Oct 2015 |
Healthcare focused investment firm OrbiMed has led a $50 million round of funding for Indian online drug marketplace Netmeds.
South Asia | 27 Oct 2015 |
BeiGene, a Chinese company backed by the likes of Hillhouse Capital and CITIC Private Equity that develops drugs to treat cancer, has filed for an IPO in the US.
Greater China | 20 Oct 2015 |
Wuxi Healthcare Venture, a corporate venture fund owned by China-based Wuxi Pharmatech, has participated in a $115 million Series E round of funding for 23andMe, a Silicon Valley-based genetics-testing company.
Greater China | 19 Oct 2015 |
Good Resources Holdings, a Hong Kong-listed investment firm controlled by Chinese billionaire Kin-Ming Cheng, will set up a joint global MA& fund worth $5 billion in conjunction with Bank of China’s Hong Kong asset management unit.
Fundraising | 16 Oct 2015 |
Updating your subscription status
The Australasian alternative assets industry is evolving and this is creating a new set of challenges for participants. Funds seeking new commitments typically require the lion share to be from offshore, the deal environment is competitive and in general market activity has slowed reflecting the regions overall macro-economic story. However, a handful of funds have had successful fundraises and it is clear that the GPs that measure up when benchmarked on a global stage will continue to drive the domestic industry forward.
This is an intriguing time as Australasian PE matures. Succession planning strategies, sourcing offshore commitments, creating a team that can deliver real operational value, customising the PE model and finding attractive investment and exit opportunities in a slow market are all key topics for debate.
Join over 300 attendees in Australia when industry leaders from across the globe meet for 2 days of high level debate and set the agenda on domestic, regional and global issues.
2-4 March 2016, The Westin Hotel, Sydney
Heading into its 15th consecutive year, the AVCJ China, Private Equity and Venture Forum, is built to be the premier gathering for the most influential private equity professionals, government officials, regulators, global investors and senior executives to meet for two days of mind-provoking debate, in-depth discussion on market trends, networking and more.
Join this annual signature event for the Private Equity and Venture Capital industry in Beijing. With over 300 leaders, from across the globe, converging to grasp the latest investment opportunities available, in the world's second largest economy.
9-10 March 2016, China World Summit Wing, Beijing